摘要
目的:探索甘精胰岛素联合利格列汀对2型糖尿病患者血糖控制效果及对胰岛β细胞损伤的保护作用。方法:选取2018年1月-2019年1月本院内分泌科门诊或住院的2型糖尿病患者180例,按随机数字表法分为A、B、C组,每组60例。A组采用甘精胰岛素单独治疗,B组采用口服利格列汀单独用药干预,C组采用甘精胰岛素+利格列汀联合治疗。比较三组治疗前后血清甘油三酯(TG)、总胆固醇(TC)、空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、餐后2 h胰岛素(2 h INS)、空腹C肽、餐后C肽、稳态模型胰岛素分泌指数(HOMA-β)及稳态模型评估法胰岛素抵抗指数(HOMA-IR)。结果:治疗后,三组血清TG、TC、FPG、2 h PG、HbA1c含量均低于治疗前(P<0.05);治疗后,C组血清TG、TC、FPG、2 h PG、HbA1c含量均低于A、B组(P<0.05);治疗后,C组FINS、2 h INS、空腹C肽、餐后C肽、HOMA-β、HOMA-IR均优于治疗前(P<0.05);C组FINS、2 h INS、空腹C肽、餐后C肽、HOMA-β、HOMA-IR均优于A、B组(P<0.05)。结论:甘精胰岛素和利格列汀联合治疗2型糖尿病患者可以保护损伤的胰岛β细胞,从而改善患者血糖和胰岛β细胞功能,具有较好的临床应用价值。
Objective:To explore the effect of in Insulin Glargine combined with Linagliptin on plasma glucose control and protection against isletβcell injury in type 2 diabetes mellitus patients.Method:From January 2018 to January 2019,180 patients with type 2 diabetes outpatient or hospitalized in the department of endocrinology of our hospital were selected and divided into groups A,B and C according to the random number table method,with 60 patients in each group.Group A was treated with insulin Glargine alone,group B was treated with oral Liglitine alone,and group C was treated with Insulin Glargine+Liglitine combined.The serum triglyceride(TG),total cholesterol(TC),fasting plasma glucose(FPG),2 h postprandial blood glucose(2 h PG),glycosylated hemoglobin(HbA1c),fasting insulin(FINS),2 h postprandial insulin(2 h INS),fasting C-peptide,postprandial C-peptide,steady state model of insulin secretion index evaluation method(HOMA-β)and the steady state model of insulin resistance index(HOMA IR)were compared before and after treatment in the three groups.Result:After treatment,serum TG,TC,FPG,2 h PG and HbA1c contents in the three groups were lower than before treatment(P<0.05).After treatment,serum TG,TC,FPG,2 h PG and HbA1c contents in group C were lower than those in groups A and B(P<0.05).After treatment,the FINS,2 h INS,fasting C-peptide,postprandial C-peptide,HOMA-β,HOMA IR in group C were better than those before treatment(P<0.05).The FINS,2 h INS,fasting C-peptide,postprandial C-peptide,HOMA-β,HOMA IR in group C were all better than those in groups A and B(P<0.05).Conclusion:The combination of Insulin Glargine and Liglitine in the treatment of type 2 diabetes can protect damaged isletβcells and improve the function of blood glucose and isletβcells in patients with type 2 diabetes,which has a good clinical application value.
作者
庞毅
刘海燕
钟劢文
罗利华
PANG Yi;LIU Haiyan;ZHONG Maiwen;LUO Lihua
出处
《中国医学创新》
CAS
2020年第1期23-26,共4页
Medical Innovation of China
基金
佛山市自筹经费类科技计划项目(2017AB003193)。
